

Special Issue

Personalized Radiation Therapy for Oncology

Message from the Guest Editor

Improvements in the targeting of genomic and immunosuppressive cancer drivers have led to major advances in the treatment of various tumors. Personalized oncology treats patients according to these specific disease mechanisms of their individual cancers and aims to improve the outcome. In the era of targeted therapies, radiation therapy has the potential to become a critical component of systemic cancer therapy. Combined-modality approaches with immunotherapy or other targeted therapies may have synergistic effects. Radiation therapy also has the possibility to personalize treatments through changes in treatment technique or the combination of different modalities, such as photon radiotherapy with particle therapy. Personalized radiation oncology can include RT technical aspects, imaging, and radiomics. The recent technology-driven improvements of treatment conformity, imaging, and adaptive radiotherapy are widening the therapeutic window of radiation oncology in the era of precision medicine and allow individual dose escalation strategies but also allow new possibilities for re-irradiation in recurrent situations.

Guest Editor

Dr. Denise Bernhardt

Department of Radiation Oncology, School of Medicine, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany

Deadline for manuscript submissions

closed (30 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/95316

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)